Genetics Pharmacy Protein 
Pharmaceutical Technology
JULY 12, 2022
A protein-based vaccine, NVX-CoV2373 is created from the genetic sequence of the SARS-CoV-2 virus’ initial strain. It is formulated with the company’s saponin-based Matrix-M and also comprises a purified protein antigen.
Pharmaceutical Technology
JULY 7, 2022
Genetic mutations, both germline and acquired, are behind a large proportion of the most debilitating and sometimes life-threatening human diseases. But scientists have struggled to find effective treatments for many of these diseases since the dawn of modern medicine.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
AUGUST 26, 2021
Shape’s RNA editing technologies can modify the RNA sequence, which makes the body’s protein building blocks. Shape’s RNA editing technology could potentially modify the amount of a key regulatory protein in the body or treat genetic diseases.
pharmaphorum
NOVEMBER 9, 2022
Haemophilia is a rare genetic bleeding disorder, occurring in one in every 5,000 (Haemophilia A) to 30,000 (Haemophilia B) male births, and is associated with an increased bleeding tendency due to a deficiency of blood clotting proteins, called coagulation factors, which are needed for the blood to clot.†. What is haemophilia?
The Pharma Data
NOVEMBER 20, 2020
Progeria and Progeroid Laminopathies are separate and distinct ultra-rare, genetic, premature aging diseases that accelerate mortality in young patients. Progeria is caused by a point mutation in the LMNA gene, yielding the farnesylated aberrant protein, progerin. ABOUT ZOKINVY (LONAFARNIB). LIMITATIONS OF USE.
The Pharma Data
OCTOBER 30, 2020
To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company’s VelocImmune ® mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19.
XTalks
AUGUST 30, 2022
What About Small Proteins and Antibodies Reaching Extracellular CNS Targets? The return of cell therapy-iPSCs (induced pluripotent stem cells) and genetically altered delivery cells. Ancillary services are also needed, such as a pharmacy to store, prepare and deliver the IP and labs such as a CSF lab to prepare samples.”.
Expert insights. Personalized for you.
162 
Let's personalize your content